CAREY CRILL: Open Payments
NPI 1457530693 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$496 in 23 payments from 9 companies in 2025. Trend: 2023 $10,308 · 2024 $4,419 · 2025 $496
Food & beverage: $496
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $161 |
| Janssen Pharmaceuticals, Inc | 2 | $138 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
| Alkermes, Inc. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Corium, LLC | 1 | $11 |
Products named: VRAYLAR, SPRAVATO, Auvelity, REXULTI, INGREZZA, ARISTADA, COBENFY, Qelbree.
Industry payments across ID — which companies pay providers there.
